Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00203502.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
PloS one - 15(2020), 4 vom: 13., Seite e0230248 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hsu, Ping-Ching [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.06.2020 Date Revised 13.12.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT00203502 Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0230248 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308831675 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308831675 | ||
| 003 | DE-627 | ||
| 005 | 20231227130234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0230248 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM308831675 | ||
| 035 | |a (NLM)32298288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hsu, Ping-Ching |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2020 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT00203502 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00203502 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a BRD9 protein, human |2 NLM | |
| 650 | 7 | |a DNA, Neoplasm |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a DNA (Cytosine-5-)-Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.37 |2 NLM | |
| 700 | 1 | |a Kadlubar, Susan A |e verfasserin |4 aut | |
| 700 | 1 | |a Siegel, Eric R |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Lora J |e verfasserin |4 aut | |
| 700 | 1 | |a Todorova, Valentina K |e verfasserin |4 aut | |
| 700 | 1 | |a Su, L Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Makhoul, Issam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 15(2020), 4 vom: 13., Seite e0230248 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:4 |g day:13 |g pages:e0230248 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0230248 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 4 |b 13 |h e0230248 | ||